Stephen Okita
Co-founder · CTO
North America
Based in San Francisco
Seed round
We're raising our seed round.
Auracle launches to the public in August 2026, and our first clinical trials in Asia begin in February 2027. This round pays for the launch, the trials, and taking our three devices through certification.
Who to talk to
One founder replies directly, depending on where you invest from.
What's already behind us
28 UK pharmacy partnerships from our prior venture
$134k UK government funding awarded
$400k angel investment, Hong Kong
~$400k in resources from the Founders Factory Healthcare accelerator
How the business is sequenced
The consumer product leads.
Aug 2026
Revenue starts with Auracle
Auracle subscriptions begin earning at consumer launch in August 2026. The CDSS cannot earn before certification, targeted for May 2027, so the consumer product carries revenue first.
One model
The consumer product feeds the clinical one
Auracle builds the bio-psycho-social history a consultation cannot gather itself. Shared by the patient, that history is the input the CDSS reasons over.
Continuous
Retention is the data pipeline
Every reply keeps the history current, so the quality of the CDSS input tracks the quality of the consumer product. Retention is the number to hold us to.
Two routes to clinical revenue
Path A
Direct to digital services
API access to our CDSS engine for clinical service providers: ambient scribes, telehealth platforms, EMRs, triage tools and more.
Path B
Direct to service providers
Sold to hospitals, GP practices, pharmacies and other providers, priced on the clinician time our service saves.
Global rollout
Approval portability, not market size, decides where we go next.
One clinical deployment can feed several regulatory dossiers at once, so we sequence by how far an approval travels, not by how big a market looks.
- Wellness launch
- Clinical trials
- Product crossover
- Asia-Pacific
- Europe & Africa
- Rest of world
Market rollout by wave
- Wellness launch: United Kingdom, United States, Canada, Australia. Auracle goes direct-to-consumer across our first four markets.
- Clinical trials: China, Hong Kong. Auracare enters clinical trials with hospitals and institutions in Hong Kong and China.
- Product crossover: Singapore. Auracare follows Auracle into its wellness markets; Auracle follows Auracare into the CAS markets.
- Asia-Pacific: Taiwan, Malaysia, Thailand, Vietnam, Indonesia, Philippines, New Zealand. Approval portability carries both products across the region.
- Europe & Africa: Ireland, France, Germany, Spain, Italy, Nigeria, Kenya, Egypt, South Africa. Expansion into European and African markets.
- Rest of world: India, Brazil, Japan, Saudi Arabia. Everywhere else, more to come.
If you're new to Auracare
This page assumes you've seen the site. If you haven't, start with these.
Auracle The consumer product: a wellness companion in your messages. Launches August 2026.Auracare CDSS, the clinical product Decision support inside the consultation, fed by our own devices. In development.How the technology works The patient state, the reasoning loop and the safety gates, explained in full.The live ontology 532,000 clinical concepts you can explore today.
Questions investors ask us
How much are you raising?
We share the target and terms directly rather than posting them here. Write to the founder for your region and we’ll walk you through the deck.
What’s live today, and what isn’t?
The ontology is live and explorable: 532,000 clinical concepts. Auracle launches to the public in August 2026. The Auracare CDSS, the clinical product, is in development and targeted for May 2027.
Who’s already backing you?
A $400k angel investment from Hong Kong, around $400k in resources from the Founders Factory Healthcare accelerator, and $134k in UK government funding. Our prior venture also built 28 UK pharmacy partnerships.
How do you handle regulation?
Auracle ships as a general-wellness product under the FD&C Act §520(o)(1)(B) exclusion, so it never diagnoses or treats. The Auracare CDSS is clinical decision support; its regulatory pathway is under active review.